Report of Foreign Issuer (6-k)
June 15 2017 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2017
Commission File Number
Novogen
Limited
(Translation of registrant’s name into English)
Level 5, 20 George Street, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☑ Form 40-F ☐
Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note
: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note
:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☑
If
“yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited
(Registrant)
Kate Hill
Kate Hill
Company Secretary
Date 15 June 2017
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of
Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents
given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
|
|
|
Name of entity
Novogen Limited
(“Novogen”)
|
|
ABN
37 063 259 754
|
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes
of section 205G of the Corporations Act.
|
|
|
|
|
Name of Director
|
|
Steven Coffey
|
|
Date of last notice
|
|
17 February 2017
|
Part 1 – Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
|
|
|
|
|
Direct or
indirect interest
|
|
Indirect
|
|
Nature of indirect interest (including
registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
|
|
Fortune 501 Pty Limited (S R Coffey Superfund)
|
|
Date of change
|
|
23 and 24 February 2017
|
|
No. of securities held prior to change
|
|
1,100,000 ordinary shares
58,747 unlisted options with exercise price of $0.40 per option, expiring 4/06/2020
|
|
Class
|
|
Ordinary shares
|
|
Number acquired
|
|
13 June 2017: 320,000 ordinary shares
|
|
Number disposed
|
|
N/A
|
|
+
|
See chapter 19 for defined terms.
|
|
|
|
|
|
01/01/2011
|
|
Appendix 3Y Page 1
|
Appendix 3Y
Change of Director’s Interest Notice
|
|
|
|
|
Value/Consideration
Note: If consideration is
non-cash,
provide
details and estimated valuation
|
|
320,000 ordinary shares at $0.057 per share
|
|
No. of securities held after change
|
|
1,420,000 ordinary shares
58,747 unlisted options with exercise price of $0.40 per option, expiring 4/06/2020
|
|
Nature of
change
Example:
on-market
trade,
off-market
trade, exercise of options, issue of securities under dividend reinvestment plan, participation in
buy-back
|
|
On market trade
|
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
|
|
|
|
|
Detail of contract
|
|
|
|
Nature of
interest
|
|
|
|
Name of
registered holder (if issued securities)
|
|
|
|
Date of
change
|
|
|
|
No. and class of
securities to which interest related prior to change
Note: Details are only
required for a contract in relation to which the interest has changed
|
|
|
|
+
|
See chapter 19 for defined terms.
|
|
|
|
|
|
Appendix 3Y Page 2
|
|
01/01/2011
|
Appendix 3Y
Change of Director’s Interest Notice
|
|
|
|
|
Interest acquired
|
|
|
|
Interest
disposed
|
|
|
|
Value/Consideration
Note: If consideration is
non-cash,
provide details and an estimated valuation
|
|
|
|
Interest after
change
|
|
|
Part 3 –
+
Closed period
|
|
|
|
|
Were the interests in the securities or contracts detailed above traded during a
+
closed period where prior written clearance was required?
|
|
Yes
|
|
If so, was prior
written clearance provided to allow the trade to proceed during this period?
|
|
Yes
|
|
If prior written
clearance was provided, on what date was this provided?
|
|
11 June 2017
|
|
+
|
See chapter 19 for defined terms.
|
|
|
|
|
|
01/01/2011
|
|
Appendix 3Y Page 3
|
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2023 to Apr 2024
